Search results

The advanced reprocessing of spent nuclear fuel is a potential key to achieve a sustainable nuclear fuel cycle and to tackle the heavy burden of nuclear...

BMF-219 is an investigational irreversible covalent inhibitor of menin. It is developed by Biomea Fusion for diabetes, lymphoma, leukemia, and multiple...

Brigimadlin (BI-907828) is a small molecule MDM2-TP53 inhibitor developed for liposarcoma. "Brigimadlin". pubchem.ncbi.nlm.nih.gov. Rinnenthal, Joerg;...

S-309309 is an experimental MGAT2 inhibitor developed as an anti-obesity drug by the Japanese company Shionogi. Phase II trial results are expected in...

George Clyde Hale (September 29, 1881 – November 3, 1948) received a patent in 1935 for the explosive ethylenedinitramine (EDNA) which was named Haleite...

HEC96719 is a tricyclic farnesoid X receptor agonist developed for non-alcoholic steatohepatitis. Cao, Shengtian; Yang, Xinye; Zhang, Zheng; Wu, Junwen;...

Omesdafexor (MET642) is a small-molecule farnesoid X receptor (FXR) agonist developed for nonalcoholic steatohepatitis and colitis. Liu, Xueqing; O'Connell...

Rencofilstat (CRV431) is a pan-cyclophilin inhibitor and analog of cyclosporine A developed for nonalcoholic steatohepatitis and hepatocellular carcinoma...

Opnurasib (JDQ-443) is a small-molecule covalent KRASG12C inhibitor developed for non-small-cell lung cancer. Weiss, Andreas; Lorthiois, Edwige; Barys...

Mezigdomide is a cereblon E3 ligase modulator developed by Bristol Myers Squibb to treat multiple myeloma. Richardson, Paul G.; Trudel, Suzanne; Quach...

EDP-305 is a non-bile acid farnesoid X receptor (FXR) agonist developed by Enanta Pharmaceuticals for non-alcoholic fatty liver disease. According to preclinical...

ZSP1601 is an experimental pan-phosphodiesterase inhibitor developed by Guangdong Raynovent Biotech for nonalcoholic steatohepatitis. Zhu, Xiaoxue; Wu...

SPH3127 is a small-molecule renin inhibitor developed by Shanghai Pharmaceuticals for hypertension and kidney disease. It is believed to be more potent...

DA-1241 is an experimental GPR119 receptor agonist developed by the South Korean company Dong-A ST for non-alcoholic steatohepatitis and type 2 diabetes...

Denifanstat (TVB-2640) is a small-molecule drug and fatty acid synthase inhibitor. Developed by Sagimet Biosciences, it has been tested in various types...

Ninerafaxstat (IMB-1018972 or IMB-101) is a cardiac mitotrope agent investigated by Imbria for diabetic cardiomyopathy, myocardial ischemia, and hypertrophic...

Prusogliptin (DBPR108) is an experimental DPP-4 inhibitor developed by CSPC Pharmaceutical Group to treat type 2 diabetes. Xu, Jianping; Ling, Hongwei;...

ZED1227 is a transglutaminase 2 (TG2) inhibitor developed by Zedira GmbH for celiac disease and nonalcoholic steatohepatitis. Schuppan, Detlef; Mäki, Markku;...

BMS-986278 is an experimental small-molecule drug and lysophosphatidic acid receptor 1 (LPA1) antagonist developed by Bristol Myers Squibb for idiopathic...

Verinurad is a selective URAT1 inhibitor developed for gout and heart failure by AstraZeneca. Johansson, Susanne; Han, David; Hunt, Thomas; Björck, Karin;...